Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Shandong DYNE Marine Biopharmaceutical Co., Ltd., Rongcheng 264300, China.
Cells. 2022 Sep 26;11(19):3001. doi: 10.3390/cells11193001.
The prevalence of obesity has reached alarming levels, which is considered a major risk factor for several metabolic diseases, including type 2 diabetes (T2D), non-alcoholic fatty liver, atherosclerosis, and ischemic cardiovascular disease. Obesity-induced chronic, low-grade inflammation may lead to insulin resistance, and it is well-recognized that macrophages play a major role in such inflammation. In the current review, the molecular mechanisms underlying macrophages, low-grade tissue inflammation, insulin resistance, and T2D are described. Also, the role of macrophages in obesity-induced insulin resistance is presented, and therapeutic drugs and recent advances targeting macrophages for the treatment of T2D are introduced.
肥胖症的患病率已经达到了惊人的水平,它被认为是几种代谢性疾病的主要危险因素,包括 2 型糖尿病(T2D)、非酒精性脂肪肝、动脉粥样硬化和缺血性心血管疾病。肥胖引起的慢性、低度炎症可能导致胰岛素抵抗,人们已经认识到巨噬细胞在这种炎症中起着主要作用。在本综述中,描述了巨噬细胞、低度组织炎症、胰岛素抵抗和 T2D 的分子机制。还介绍了巨噬细胞在肥胖诱导的胰岛素抵抗中的作用,以及针对巨噬细胞治疗 T2D 的治疗药物和最新进展。
Cells. 2022-9-26
Eur J Med Res. 2024-10-16
Nutrients. 2025-8-21
Curr Issues Mol Biol. 2025-5-9
Diabetol Metab Syndr. 2025-7-18
Front Cell Dev Biol. 2025-6-30
Front Immunol. 2022
Front Endocrinol (Lausanne). 2022
Diabetol Int. 2020-12-15
Annu Rev Pathol. 2019-11-1